In a significant move to address high prescription drug costs, President Donald Trump announced a deal with pharmaceutical giant AstraZeneca, which will result in reduced drug prices for Medicaid and other programs. The agreement aims to alleviate the financial burden on Americans struggling with expensive medications, with AstraZeneca committing to lower prices in exchange for tariff reprieves. The announcement, made during a press conference at the White House, has raised questions about potential ethical and legal implications, as well as the impact on drug prices overall. This comes amidst ongoing discussions about healthcare affordability and industry practices in the United States.